{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:22:25Z","timestamp":1786980145080,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s00417-020-04755-z","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T04:02:52Z","timestamp":1590465772000},"page":"1607-1615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Optical coherence tomography characteristics of taxane-induced macular edema and other multimodal imaging findings"],"prefix":"10.1007","volume":"258","author":[{"given":"Joel M.","family":"Perez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Maruyama-Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Bailey","family":"Freund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9266-3589","authenticated-orcid":false,"given":"Anna C. S.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,26]]},"reference":[{"issue":"2","key":"4755_CR1","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1159\/000477897","volume":"10","author":"T Yokoe","year":"2017","unstructured":"Yokoe T, Fukada I, Kobayashi K et al (2017) Cystoid macular edema during treatment with paclitaxel and bevacizumab in a patient with metastatic breast cancer: a case report and literature review. Case Rep Oncol 10(2):605\u2013612","journal-title":"Case Rep Oncol"},{"issue":"10","key":"4755_CR2","doi-asserted-by":"publisher","first-page":"867","DOI":"10.3109\/02713683.2011.594202","volume":"36","author":"A Eisner","year":"2011","unstructured":"Eisner A, Luoh S (2011) Breast cancer medications and vision: effects of treatments for early-stage disease. Curr Eye Res 36(10):867\u2013885","journal-title":"Curr Eye Res"},{"issue":"10","key":"4755_CR3","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1023\/A:1008249230056","volume":"8","author":"L Hofstra","year":"1997","unstructured":"Hofstra L, de Vries E, Willemse P (1997) Ophthalmic toxicity following paclitaxel infusion. Ann Oncol 8(10):1053\u20131053","journal-title":"Ann Oncol"},{"issue":"2","key":"4755_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2165\/00002018-200831020-00003","volume":"31","author":"J Li","year":"2008","unstructured":"Li J, Tripathi R, Tripathi B (2008) Drug-induced ocular disorders. Drug Saf 31(2):127\u2013141","journal-title":"Drug Saf"},{"issue":"4","key":"4755_CR5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/00006324-200304000-00004","volume":"80","author":"B Teitelbaum","year":"2003","unstructured":"Teitelbaum B, Tresley D (2003) Cystic maculopathy with normal capillary permeability secondary to docetaxel. Optom Vis Sci 80(4):277\u2013279","journal-title":"Optom Vis Sci"},{"issue":"5","key":"4755_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/archopht.125.5.709","volume":"125","author":"M Joshi","year":"2007","unstructured":"Joshi M (2007) Paclitaxel maculopathy. Arch Ophthalmol 125(5):709","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"4755_CR7","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3341\/kjo.2012.26.5.394","volume":"26","author":"N Koo","year":"2012","unstructured":"Koo N, Kim Y (2012) A case of paclitaxel-induced maculopathy treated with methazolamide. Korean J Ophthalmol 26(5):394","journal-title":"Korean J Ophthalmol"},{"issue":"1","key":"4755_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/eye.2012.228","volume":"27","author":"J Ehlers","year":"2012","unstructured":"Ehlers J, Rayess H, Steinle N (2012) Topical dorzolamide therapy for taxane-related macular oedema. Eye. 27(1):102\u2013104","journal-title":"Eye."},{"issue":"5","key":"4755_CR9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3341\/kjo.2012.26.5.388","volume":"26","author":"D Ham","year":"2012","unstructured":"Ham D, Lee J, Kim H, Yun I (2012) A case of cystoid macular edema associated with paclitaxel chemotherapy. Korean J Ophthalmol 26(5):388","journal-title":"Korean J Ophthalmol"},{"issue":"33","key":"4755_CR10","doi-asserted-by":"publisher","first-page":"e684","DOI":"10.1200\/JCO.2010.30.3750","volume":"28","author":"C Murphy","year":"2010","unstructured":"Murphy C, Walsh J, Hudis C, Lake D, Theodoulou M (2010) Cystoid macular edema secondary to nab-paclitaxel therapy. J Clin Oncol 28(33):e684\u2013e687","journal-title":"J Clin Oncol"},{"issue":"3","key":"4755_CR11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10792-012-9558-9","volume":"32","author":"TI Kuznetcova","year":"2012","unstructured":"Kuznetcova TI, Cech P, Herbort CP (2012) The mystery of angiographically silent macular oedema due to taxanes. Int Ophthalmol 32(3):299\u2013304","journal-title":"Int Ophthalmol"},{"key":"4755_CR12","first-page":"1","volume":"2015","author":"N Matsuoka","year":"2015","unstructured":"Matsuoka N, Hasebe H, Mayama T, Fukuchi T (2015) Sub-tenon injections of triamcinolone acetonide had limited effect on cystoid macular edema secondary to nanoparticle albumin-bound paclitaxel (abraxane). Case Rep Ophthalmol Med 2015:1\u20134","journal-title":"Case Rep Ophthalmol Med"},{"issue":"4","key":"4755_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3109\/15569527.2014.996294","volume":"34","author":"P Freitas-da-Costa","year":"2015","unstructured":"Freitas-da-Costa P, Brand\u00e3o E, Bragan\u00e7a T, Falc\u00e3o-Reis F, Carneiro A (2015) Multimodal imaging in paclitaxel-induced macular edema: the microtubule disfunction. Cutan Ocul Toxicol 34(4):347\u2013349","journal-title":"Cutan Ocul Toxicol"},{"key":"4755_CR14","doi-asserted-by":"publisher","unstructured":"Hassall MM, Andrew NH (2016) Single-eye trial of a topical carbonic anhydrase inhibitor versus intravitreal bevacizumab for the treatment of taxane drug-induced cystoid macula oedema. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr2015212733","DOI":"10.1136\/bcr2015212733"},{"issue":"26","key":"4755_CR15","doi-asserted-by":"publisher","first-page":"e11229","DOI":"10.1097\/MD.0000000000011229","volume":"97","author":"C-H Shih","year":"2018","unstructured":"Shih C-H, Lee Y-C (2018) Impaired retinal pigment epithelium in paclitaxel-induced macular edema. Medicine 97(26):e11229","journal-title":"Medicine"},{"issue":"3","key":"4755_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/08820530701457373","volume":"22","author":"DG Telander","year":"2007","unstructured":"Telander DG, Sarraf D (2007) Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome. Semin Ophthalmol 22(3):151\u2013153","journal-title":"Semin Ophthalmol"},{"issue":"10","key":"4755_CR17","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1200\/JCO.1998.16.10.3426","volume":"16","author":"K Semb","year":"1998","unstructured":"Semb K, Aamdal S, Oian P (1998) Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 16(10):3426\u20133432","journal-title":"J Clin Oncol"},{"issue":"6","key":"4755_CR18","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0002-9394(02)02296-1","volume":"135","author":"M Spirn","year":"2003","unstructured":"Spirn M, Warren F, Guyer D, Klancnik J, Spaide R (2003) Optical coherence tomography findings in nicotinic acid maculopathy. Am J Ophthalmol 135(6):913\u2013914","journal-title":"Am J Ophthalmol"},{"key":"4755_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/isbn.978-3-318-06033-1","volume-title":"Macular edema","author":"G Coscas","year":"2017","unstructured":"Coscas G, Loewenstein A, Cunha-Vaz J, Soubrane G (2017) Macular edema, 2nd edn. S. Karger Ag, Basel, pp 1\u201310","edition":"2"},{"issue":"8","key":"4755_CR20","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40265-013-0055-x","volume":"73","author":"OE Makri","year":"2013","unstructured":"Makri OE, Georgalas I, Georgakopoulos CD (2013) Drug-induced macular edema. Drugs. 73(8):789\u2013802","journal-title":"Drugs."},{"issue":"2","key":"4755_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3892\/mco.2017.1296","volume":"7","author":"E Bassi","year":"2017","unstructured":"Bassi E, Loizzi V, Furino C et al (2017) Cystoid macular edema secondary to paclitaxel therapy for ovarian cancer: a case report. Mol Clin Oncol 7(2):285\u2013287","journal-title":"Mol Clin Oncol"},{"issue":"2","key":"4755_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10384-017-0552-7","volume":"62","author":"N Nomi","year":"2017","unstructured":"Nomi N, Ota M, Fukumura M et al (2017) Indocyanine green angiography findings of cystoid macular edema secondary to paclitaxel therapy. Jpn J Ophthalmol 62(2):163\u2013167","journal-title":"Jpn J Ophthalmol"},{"issue":"3","key":"4755_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000456653","volume":"62","author":"E Chelala","year":"2017","unstructured":"Chelala E, Arej N, Antoun J et al (2017) Central macular thickness monitoring after a taxane-based therapy in visually asymptomatic patients. Chemotherapy. 62(3):199\u2013204","journal-title":"Chemotherapy."},{"issue":"8","key":"4755_CR24","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/S0968-0896(01)00103-1","volume":"9","author":"DV Crabtree","year":"2001","unstructured":"Crabtree DV, Ojima I, Geng X, Adler AJ (2001) Tubulins in the primate retina: evidence that xanthophylls may be endogenous ligands for the paclitaxel-binding site. Bioorg Med Chem 9(8):1967\u20131976","journal-title":"Bioorg Med Chem"},{"issue":"3","key":"4755_CR25","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00417-011-1642-8","volume":"250","author":"K Meyer","year":"2011","unstructured":"Meyer K, Klink T, Ugurel S, Br\u00f6cker E (2011) Regression of paclitaxel-induced maculopathy with oral acetazolamide. Graefes Arch Clin Exp Ophthalmol 250(3):463\u2013464","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-04755-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-020-04755-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-04755-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T19:31:23Z","timestamp":1621971083000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-020-04755-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,26]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["4755"],"URL":"https:\/\/doi.org\/10.1007\/s00417-020-04755-z","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,26]]},"assertion":[{"value":"14 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AT speaks and receives sponsorship for Zeis, Nidek, Bayer, and Novartis and travel grants from Allergan and Mandarin Optics. KBF is a consultant to Genentech, Optovue, Zeiss, Heidelberg Engineering, Allergan, and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Health Insurance Portability and Accountability Act of 1996 and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}